Abstract

Review Article

Mechanisms and Clinical Research Progress of Rituximab in the Treatment of Adult Minimal Change Disease

Yin Zheng, Hu Haofei and Wan Qijun*

Published: 08 August, 2023 | Volume 7 - Issue 2 | Pages: 057-062

Introduction: Minimal change disease (MCD) is a common subtype of primary nephrotic syndrome in adults. The pathogenesis of MCD is still not well understood, but some studies suggest that MCD is a T cell-mediated disease related to podocyte dysfunction. Previous research has also indicated the crucial role of B cells in the pathogenesis of MCD. Rituximab (RTX) is a recombinant chimeric mouse/human antibody targeting CD20 antigen. In recent years, RTX has been increasingly used in adult MCD patients.
Methodology: We searched the PubMed database using the keywords “Minimal change disease”, “Nephrotic syndrome”, and “Rituximab” and obtained a total of 140 articles. We will now provide a literature review based on these 140 articles, according to our research topic.
Discussion: This article provides an overview of the mechanisms and clinical research progress of RTX in the treatment of adult MCD. We have also discussed the current treatment methods for MCD, exploring the potential of using RTX as a first-line therapy for refractory adult MCD.
Conclusion: MCD is a common pathological type of nephrotic syndrome, and the exact mechanisms are still not fully understood. Although RTX as a treatment of adult MCD has shown promising clinical results in patients with refractory adult MCD, the safety and efficacy of RTX still lack high-quality clinical evidence. Further research is needed to explore the pathogenesis of MCD and the RTX treatment for MCD.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001110 Cite this Article Read Full Article PDF

Keywords:

Minimal change disease; Rituximab; Nephrotic syndrome

References

  1. Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Maas R, Mayer G, Moiseev S, Muto M, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Segelmark M, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A; RITERM study group. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? Autoimmun Rev. 2020 Nov;19(11):102671. doi: 10.1016/j.autrev.2020.102671. Epub 2020 Sep 15. PMID: 32942039.
  2. Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis. 1987 Sep;10(3):157-71. doi: 10.1016/s0272-6386(87)80170-1. PMID: 3307394.
  3. Fogo A, Hawkins EP, Berry PL, Glick AD, Chiang ML, MacDonell RC Jr, Ichikawa I. Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int. 1990 Jul;38(1):115-23. doi: 10.1038/ki.1990.175. PMID: 2385079.
  4. Shirato I. Podocyte process effacement in vivo. Microsc Res Tech. 2002 May 15;57(4):241-6. doi: 10.1002/jemt.10082. PMID: 12012392.
  5. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9( Suppl 3): S1-S155.
  6. Maas RJ, Deegens JK, Smeets B, Moeller MJ, Wetzels JF. Minimal change disease and idiopathic FSGS: manifestations of the same disease. Nat Rev Nephrol. 2016 Dec;12(12):768-776. doi: 10.1038/nrneph.2016.147. Epub 2016 Oct 17. PMID: 27748392.
  7. Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, Ticchioni M, Rosenthal A, Benzaken S, Bernard G, Lambeau G, Ronco P, Esnault VLM. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1173-1182. doi: 10.2215/CJN.11791018. Epub 2019 Jul 24. PMID: 31340979; PMCID: PMC6682825.
  8. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet. 2002 Sep 21;360(9337):923-4. doi: 10.1016/S0140-6736(02)11042-7. Erratum in: Lancet 2002 Dec 21-28;360(9350):2090. PMID: 12354476.
  9. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008 Jan;73(1):117-25. doi: 10.1038/sj.ki.5002628. Epub 2007 Oct 17. PMID: 17943078.
  10. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. 2010 Dec;5(12):2188-98. doi: 10.2215/CJN.05080610. Epub 2010 Aug 12. PMID: 20705965; PMCID: PMC2994079.
  11. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasà M, Remuzzi G. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012 Aug;23(8):1416-25. doi: 10.1681/ASN.2012020181. Epub 2012 Jul 19. PMID: 22822077; PMCID: PMC3402291.
  12. Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, Tsuruta Y, Ochi A, Amemiya N, Mochizuki T, Uchida K, Tsuchiya K, Nitta K. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant. 2013 May;28(5):1225-32. doi: 10.1093/ndt/gfs515. Epub 2012 Dec 13. PMID: 23239834.
  13. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974 Sep 7;2(7880):556-60. doi: 10.1016/s0140-6736(74)91880-7. PMID: 4140273.
  14. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003 Aug 23;362(9384):629-39. doi: 10.1016/S0140-6736(03)14184-0. PMID: 12944064.
  15. Elie V, Fakhoury M, Deschênes G, Jacqz-Aigrain E. Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives. Pediatr Nephrol. 2012 Aug;27(8):1249-56. doi: 10.1007/s00467-011-1947-1. Epub 2011 Jun 28. PMID: 21710250.
  16. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 1991 Sep;40(3):453-60. doi: 10.1038/ki.1991.232. PMID: 1787645.
  17. Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, Pawlak A, Audard V, Ollero M, Guigonis V, Sahali D. NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome. J Autoimmun. 2018 Mar;88:91-102. doi: 10.1016/j.jaut.2017.10.006. Epub 2017 Oct 19. PMID: 29056249.
  18. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905. PMID: 20647199; PMCID: PMC3137658.
  19. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011 Jun 1;3(85):85ra46. doi: 10.1126/scitranslmed.3002231. PMID: 21632984; PMCID: PMC3719858.
  20. Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery. Nephrol Dial Transplant. 2012 Mar;27(3):1083-9. doi: 10.1093/ndt/gfr405. Epub 2011 Aug 1. PMID: 21810762.
  21. Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal Change Disease. Clin J Am Soc Nephrol. 2017 Feb 7;12(2):332-345. doi: 10.2215/CJN.05000516. Epub 2016 Dec 9. PMID: 27940460; PMCID: PMC5293332.
  22. Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Ravà L, Ruggiero B, Emma F, Vivarelli M. B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. J Am Soc Nephrol. 2016 Jun;27(6):1811-22. doi: 10.1681/ASN.2015050523. Epub 2015 Nov 13. PMID: 26567244; PMCID: PMC4884116.
  23. Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med. 2014 Mar 27;370(13):1268-70. doi: 10.1056/NEJMc1308488. PMID: 24670185.
  24. Sinha R, Agrawal N, Xue Y, Chanchlani R, Pradhan S, Raina R, Marks SD. Use of rituximab in paediatric nephrology. Arch Dis Child. 2021 Nov;106(11):1058-1065. doi: 10.1136/archdischild-2020-321211. Epub 2021 Jun 10. PMID: 34112638; PMCID: PMC8543203.
  25. Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol. 2015 Jul 27;6:368. doi: 10.3389/fimmu.2015.00368. PMID: 26284063; PMCID: PMC4515552.
  26. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010 Apr;47(2):115-23. doi: 10.1053/j.seminhematol.2010.01.011. PMID: 20350658; PMCID: PMC2848172.
  27. Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017 Oct;34(10):2232-2273. doi: 10.1007/s12325-017-0612-x. Epub 2017 Oct 5. PMID: 28983798; PMCID: PMC5656728.
  28. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013 Apr;13(4):227-42. doi: 10.1038/nri3405. Epub 2013 Mar 8. Erratum in: Nat Rev Immunol. 2013 Jul;13(7):542. PMID: 23470321; PMCID: PMC3786574.
  29. Hoffman W, Lakkis FG, Chalasani G. B Cells, Antibodies, and More. Clin J Am Soc Nephrol. 2016 Jan 7;11(1):137-54. doi: 10.2215/CJN.09430915. Epub 2015 Dec 23. PMID: 26700440; PMCID: PMC4702236.
  30. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol. 2007 Apr;123(1):66-73. doi: 10.1016/j.clim.2006.12.006. Epub 2007 Jan 31. PMID: 17275413.
  31. Bhatia D, Sinha A, Hari P, Sopory S, Saini S, Puraswani M, Saini H, Mitra DK, Bagga A. Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome. Pediatr Res. 2018 Oct;84(4):520-526. doi: 10.1038/s41390-018-0088-7. Epub 2018 Jul 9. PMID: 29983411.
  32. Bonanni A, Calatroni M, D'Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G, Bertelli R, Di Donato A, Bruschi M, Canepa A, Piaggio G, Ravani P, Ghiggeri GM. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol. 2018 Jun;84(6):1238-1249. doi: 10.1111/bcp.13548. Epub 2018 Mar 25. PMID: 29436729; PMCID: PMC5980330.
  33. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008 Jul;8(7):523-32. doi: 10.1038/nri2343. PMID: 18566595; PMCID: PMC2665249.
  34. Li X, Zheng Y. Regulatory T cell identity: formation and maintenance. Trends Immunol. 2015 Jun;36(6):344-53. doi: 10.1016/j.it.2015.04.006. Epub 2015 May 13. PMID: 25981968; PMCID: PMC4458194.
  35. Wang CS, Liverman RS, Garro R, George RP, Glumova A, Karp A, Jernigan S, Warshaw B. Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol. 2017 May;32(5):835-841. doi: 10.1007/s00467-017-3621-8. Epub 2017 Feb 17. PMID: 28213687; PMCID: PMC5373940.
  36. Dhaeze T, Stinissen P, Liston A, Hellings N. Humoral autoimmunity: a failure of regulatory T cells? Autoimmun Rev. 2015 Aug;14(8):735-41. doi: 10.1016/j.autrev.2015.04.006. Epub 2015 Apr 23. PMID: 25913138.
  37. Prasad N, Jaiswal AK, Agarwal V, Yadav B, Sharma RK, Rai M, Singh H, Chaturvedi S, Singh A. Differential alteration in peripheral T-regulatory and T-effector cells with change in P-glycoprotein expression in Childhood Nephrotic Syndrome: A longitudinal study. Cytokine. 2015 Apr;72(2):190-6. doi: 10.1016/j.cyto.2014.12.028. Epub 2015 Feb 4. PMID: 25661194.
  38. Jaiswal A, Prasad N, Agarwal V, Yadav B, Tripathy D, Rai M, Nath M, Sharma RK, Modi DR. Regulatory and effector T cells changes in remission and resistant state of childhood nephrotic syndrome. Indian J Nephrol. 2014 Nov;24(6):349-55. doi: 10.4103/0971-4065.132992. PMID: 25484527; PMCID: PMC4244713.
  39. Kimata T, Tsuji S, Kino J, Kitao T, Yamanouchi S, Kaneko K. Close association between proteinuria and regulatory T cells in patients with idiopathic nephrotic syndrome. Pediatr Nephrol. 2013 Apr;28(4):667-9. doi: 10.1007/s00467-012-2387-2. Epub 2012 Dec 24. PMID: 23263711.
  40. Bertelli R, Bonanni A, Di Donato A, Cioni M, Ravani P, Ghiggeri GM. Regulatory T cells and minimal change nephropathy: in the midst of a complex network. Clin Exp Immunol. 2016 Feb;183(2):166-74. doi: 10.1111/cei.12675. Epub 2015 Oct 12. PMID: 26147676; PMCID: PMC4711159.
  41. Liu LL, Qin Y, Cai JF, Wang HY, Tao JL, Li H, Chen LM, Li MX, Li XM, Li XW. Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin Immunol. 2011 Jun;139(3):314-20. doi: 10.1016/j.clim.2011.02.018. Epub 2011 Mar 1. PMID: 21450528.
  42. Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, Amadori S. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008 Aug 15;112(4):1147-50. doi: 10.1182/blood-2007-12-129262. Epub 2008 Mar 28. PMID: 18375792.
  43. Mélet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. 2013 Nov;65(11):2783-90. doi: 10.1002/art.38107. PMID: 23918413.
  44. Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J, Guigonis V, Ducret F, Presne C, Pirson Y, Hourmant M, Glachant JC, Vendrely B, Moranne O, Faguer S, Chauveau D. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant. 2014 Nov;29(11):2084-91. doi: 10.1093/ndt/gfu209. Epub 2014 Jun 11. PMID: 24920841.
  45. Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, Deschênes G, Ronco PM, Plaisier EM, Dahan KY. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013 Mar;83(3):511-6. doi: 10.1038/ki.2012.444. Epub 2013 Jan 16. PMID: 23325085.
  46. DaSilva I, Huerta A, Quintana L, Redondo B, Iglesias E, Draibe J, Praga M, Ballarín J, Díaz-Encarnación M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain. BioDrugs. 2017 Jun;31(3):239-249. doi: 10.1007/s40259-017-0221-x. PMID: 28534103.
  47. Liu D, Zhou Z, Wang M, Nie S, Li J, Hu B, He W, Wang G, Ai J. Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease. BMC Nephrol. 2021 Jul 1;22(1):242. doi: 10.1186/s12882-021-02437-4. PMID: 34210283; PMCID: PMC8247102.
  48. Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G; Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014 Apr;25(4):850-63. doi: 10.1681/ASN.2013030251. Epub 2014 Jan 30. PMID: 24480824; PMCID: PMC3968490.
  49. Brown LC, Jobson MA, Payan Schober F, Chang EH, Falk RJ, Nachman PH, Pendergraft WF. The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy. Am J Nephrol. 2017;45(4):365-372. doi: 10.1159/000464475. Epub 2017 Mar 18. PMID: 28315862; PMCID: PMC5952605.
  50. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021. PMID: 34556256.
  51. Expert Consensus on the Application of Rituximab in Glomerulonephritis. (2022) Chinese Journal of Nephrology. 38(2): 151-160.

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?